Clarivate Epidemiology’s coverage of respiratory syncytial virus (RSV) infection comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (United…
Clarivate’s Epidemiology’s coverage of the RSV vaccine comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France,…
Clarivate Epidemiology’s coverage of human papillomavirus (HPV) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States,…
Myasthenia gravis (MG) is an acquired disorder of neuromuscular transmission, which occurs due to the production of pathogenic autoantibodies that bind to components of the neuromuscular junction,…
Clarivate Epidemiology’s coverage of gastrointestinal stromal tumor (GIST) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence…
Clarivate Epidemiology’s coverage of gastrointestinal stromal tumor (GIST) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence…
Clarivate Epidemiology’s coverage of gastrointestinal stromal tumor (GIST) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence…
Clarivate Epidemiology’s coverage of gastrointestinal stromal tumor (GIST) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence…
Clarivate Epidemiology’s coverage of gastrointestinal stromal tumor (GIST) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence…
Clarivate Epidemiology’s coverage of gastrointestinal stromal tumor (GIST) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence…
Clarivate’s extended worldwide coverage is the first and only evidence-based data set of epidemiological forecasts for key GIST patient populations covering 171 countries and more than 99% of the…